middle.news
Imugene’s Azer-cel CAR T Trial Hits 75% Response Rate in Tough Lymphoma Cases
8:42am on Monday 14th of July, 2025 AEST
•
Healthcare
Read Story
Imugene’s Azer-cel CAR T Trial Hits 75% Response Rate in Tough Lymphoma Cases
8:42am on Monday 14th of July, 2025 AEST
Key Points
75% overall response rate with 55% complete responses in Phase 1b trial
Durable responses observed, including one patient cancer-free beyond 15 months
Trial expanded to include CAR T naïve patients with other lymphoma subtypes
FDA Fast Track designation secured, pivotal study discussions planned for Q4 2025
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Imugene (ASX:IMU)
OPEN ARTICLE